Shinoura N, Sakurai S, Asai A, Kirino T, Hamada H
Department of Molecular Biotherapy Research, Cancer Chemotherapy Center, Cancer Institute, Toshima-ku, Tokyo 170-8455, Japan.
Jpn J Cancer Res. 2000 Oct;91(10):1028-34. doi: 10.1111/j.1349-7006.2000.tb00881.x.
Suicide gene therapy utilizing the herpes simplex thymidine kinase (HSVtk) / ganciclovir (GCV) system has been performed to kill cancer cells. However, the low transduction efficiency of HSVtk gene into cancer cells critically limits its efficacy in cancer treatment in clinical situations. To improve delivery of the HSVtk gene into cancer cells, we transduced U-87MG and U-373MG glioma cells with adenovirus (Adv) vectors with a fiber mutant, F / K20, which has a stretch of 20 lysine residues added at the C-terminus of the fiber, for the HSVtk gene (Adv-TK-F / K20), and compared the cytopathic effect of Adv-TK-F / K20 with that of the Adv for HSVtk with wild-type fiber (Adv-TK). The cytopathic effect of Adv-TK-F / K20 in U-87MG and U-373MG cells was approximately 140 and 40 times, respectively, stronger than that of Adv-TK. At the same multiplicity of infection (MOI) in each cell line, Adv-TK-F / K20 induced a higher degree of apoptosis (U-87MG, 35%; U-373MG, 77%) than Adv-TK (U-87MG, 0.11%; U-373MG, 27%) in U-87MG (MOI 0.03) and U-373MG cells (MOI 0.1). Cleavage of poly(ADP-ribose)polymerase (PARP) was more marked in the cells that were infected with Adv-TK-F / K20 than in cells that were infected with Adv-TK. These results indicate that gene therapy utilizing Adv-TK-F / K20 may be a promising therapeutic modality for the treatment of gliomas.
利用单纯疱疹病毒胸苷激酶(HSVtk)/更昔洛韦(GCV)系统进行自杀基因治疗已用于杀死癌细胞。然而,HSVtk基因转导至癌细胞的效率较低,这严重限制了其在临床癌症治疗中的疗效。为了提高HSVtk基因向癌细胞的递送效率,我们用一种纤维突变体F/K20的腺病毒(Adv)载体转导U-87MG和U-373MG胶质瘤细胞,该载体在纤维的C末端添加了一段20个赖氨酸残基用于携带HSVtk基因(Adv-TK-F/K20),并将Adv-TK-F/K20的细胞病变效应与具有野生型纤维的HSVtk腺病毒(Adv-TK)的细胞病变效应进行比较。Adv-TK-F/K20在U-87MG和U-373MG细胞中的细胞病变效应分别比Adv-TK强约140倍和40倍。在每个细胞系相同的感染复数(MOI)下,Adv-TK-F/K20在U-87MG(MOI 0.03)和U-373MG细胞(MOI 0.1)中诱导的凋亡程度(U-87MG为35%;U-373MG为77%)高于Adv-TK(U-87MG为0.11%;U-373MG为27%)。聚(ADP-核糖)聚合酶(PARP)的切割在感染Adv-TK-F/K20的细胞中比在感染Adv-TK的细胞中更明显。这些结果表明,利用Adv-TK-F/K20的基因治疗可能是一种有前景的胶质瘤治疗方式。